Pionyr Immunotherapeutics Secures $8,000,000 Series A Funding

  • Feed Type
  • Date
    1/5/2017
  • Company Name
    Pionyr Immunotherapeutics
  • Mailing Address
    953 Indiana St. San Francisco, CA 94107 USA
  • Company Description
    Pionyr develops drugs to perform exceptional fine-tuning of immune responses. This goal addresses a current and justified excitement about immunotherapy and introduces technology to rapidly identify and target novel arms of the immune response, within the tumor microenvironment (TME).
  • Website
    http://www.precisionimmune.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    OrbiMed
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    Osage Partners
  • Venture Investor
    Mission Bay Capital
  • Venture Investor
    Investor
  • Venture Investor
    Investor
  • Venture Investor
    Investor
  • Venture Investor
    Investor